Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:32 2025-01-10 EST			5-day change	1st Jan Change
91.09 ^CHF	-0.60%		+2.33%	+2.69%

01-09	NOVARTIS AG : Goldman Sachs remains Neutral	ZD
01-09	Light Horse Therapeutics Inc announced that it expects to receive $87 million in funding from Versant Venture Management, LLC, Bristol-Myers Squibb Company, AbbVie Ventures, Inc., Taiho Ventures, LLC, Mubadala Capital, Novartis AG	CI

US Court Rejects Novartis' Appeal to Block Heart Failure Drug's Generic Version

December 04, 2024 at 11:49 pm

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Novartis AG

NOVARTIS AG : Goldman Sachs remains Neutral	01-09	ZD
Light Horse Therapeutics Inc announced that it expects to receive $87 million in funding from Versant Venture Management, LLC, Bristol-Myers Squibb Company, AbbVie Ventures, Inc., Taiho Ventures, LLC, Mubadala Capital, Novartis AG	01-08	CI
NOVARTIS AG : Gets a Neutral rating from Berenberg	01-07	ZD
NOVARTIS AG : Bernstein reiterates its Buy rating	01-07	ZD
A poor 2024 increases the odds of a brighter 2025	01-02
Experts expect more IPOs and takeovers in 2025	01-02	RE
Swiss Stocks Close Higher Ahead of New Year Break	12-30	MT
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study	12-30	MT
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint	12-30	MT
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint	12-30	MT
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA	12-30	DJ
Novartis Announces Positive Topline Results from the Phase III Steer Study	12-30	CI
Sector Update: Health Care Stocks Lower in Late Afternoon Trading	12-27	MT
Sector Update: Health Care	12-27	MT
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, US Appeals Court Rules	12-27	MT
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, Appeals Court Rules	12-27	MT
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules	12-27	RE
Novartis to Close MorphoSys Sites, Affecting 330 Jobs	12-19	MT
Novartis to Close MorphoSys Sites, Affecting 330 Jobs	12-19	MT
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports	12-19	RE
Borealis Biosciences, Inc. announced that it has received CAD 245.0644 million in funding from Versant Venture Management, LLC, Novartis AG, Westlake Village BioPartners	12-18	CI
Banzai International, Inc. Appoints Nancy Norton as Chief Legal Officer	12-18	CI
BioAge Stock Advances 14% On Novartis Research Collaboration	12-18	DJ
BioAge Labs Says it is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases	12-18	MT
Bioage Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies That Address Age-Related Diseases and Conditions	12-18	CI

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

2025-01-12 - JP Morgan Healthcare Conference

More about the company